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Background: Tigecycline (TIG), a member of a new class
of antimicrobials (glycylcyclines), has been shown to have
potent expanded broad spectrum activity against most
commonly encountered species responsible for commu-
nity and hospital acquired infections. The T.E.S.T. program
determined the in vitro activity of tigecycline compared
to amoxicillin-clavulanic acid, piperacillin-tazobactam,
levoﬂoxacin, ceftriaxone, linezolid (LZD), minocycline, van-
comycin (VAN), ampicillin (AM), penicillin, and imipenem
against VRE collected from hospitals globally throughout
2004—2007.
Methods: 742 VRE (110 Enterococcus faecalis, 632 E.
faecium) clinical isolates were identiﬁed to the species
level at each participating site and conﬁrmed by the cen-
tral laboratory. Minimum Inhibitory Concentrations (MICs)
were determined by the local laboratory using supplied
broth microdilution panels and interpreted according to
CLSI guidelines with tigecycline susceptible deﬁned as
≤0.25mcg/mL.
Results: %S of all VRE to TIG, LZD, and MINwere 100, 96.4,
and 72.2, respectively. For E. faecalis strains, the three most
active drugs were TIG (100%), LZD (100%), and AM (100%).
For E. faecium, the three most active drugs were TIG (100%),
LZD (95.7%), and MIN (74.4%). There were signiﬁcant dif-
ferences in VRE rates between North America (E. faecalis
4.7%, E. faecium 65.8%), Europe (E. faecalis 1.3%, E. faecium
16.4%), and Asia (E.faecalis 0%, E.faecium 30%).
Conclusions: TIG exhibited outstanding activity against
VRE, inhibiting 100% of strains with MICs ≤0.25mcg/ml
(MIC90 = 0.06), surpassing LZD as the most active drug in
this study. The exceptionally broad spectrum of TIG, which
includes many other multi-resistant gram-positive and gram-
negative bacteria in addition to VRE, will make it a very
attractive addition to hospital formularies.
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Recently, the abuse of the antibiotics induces the appear-
ance of the drug resistant bacteria Therefore, it is necessary
to develop an alternative reagent that takes the place of the
antibiotics. Porcine lysozyme (PLY), a natural anti-bacillus
protein, is one of the promising candidate. Therefore, it
is expected to mass-produce PLY with the genetic engi-
neering technique. However, it has been not succeeded
because of its unstable DNA sequence. To stabilize it, the
codon of Asp102 was substituted (gac♦gat). This modiﬁed
PLY gene (length: 484 bp) was synthesized with 9 short DNA
oligomers by SPR method and PCR extension, and expressed
in insect cell line (expresSF+) using baculovirus expression
system. The efﬁciency of recombinant PLY production was
high (more than 50mg/L) in the expresSF+ cell culture ﬂuid.
The product was puriﬁed and analyzed its molecular weight
by mass spectrometry and N-terminal sequence by peptide
sequencer. The results proved that the expressed recombi-
nant PLY was the same as the natural type. When having
compared it with human lysozyme and chicken egg white
lysozyme, PLY showed stronger lysing activity against M.
lysodeikticus than human and chicken egg white lysozyme
in the high salt or high pH conditions. This research was
ﬁnanced by the Japan Livestock Technology Association.
doi:10.1016/j.ijid.2008.05.725
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Background: Methicillin-resistant Staphylococcus aureus
(MRSA) continues to be an ever-ending threat worldwide as
nosocomial or community-acquired (CA) pathogen. SCCmec
being the key component for methicillin resistance differ-
entiates nosocomial and community strains based on their
types. Despite of the increasing prevalence of MRSA in
Malaysia, SCCmec types of local strains are unknown. The
aim of the study is to investigate the SCCmec types of local
isolates and identify the predominant type in hospital set-
ting.
Methods: Thirty-eight non duplicate MRSA isolates repre-
senting various clinical presentations isolated from a tertiary
hospital during Oct 2006 to February 2007 was subjected to
SCCmec typing. Reference strains for SCCmec types I, II, III,
IV, V were included.
Results: Of 38 MRSA isolates 27 (71%) were found to carry
SCCmec type V with two (7.4%) hyper-virulent PVL produc-
ers, and 11 (29%) carried SCCmec type III. None of other
SCCmec types were observed. No signiﬁcant relationship was
found between the SCCmec types and clinical specimen as
both types were mostly isolated from pus, blood and tra-
cheal aspirate. However, two isolates from urine samples
carried SCCmec type V. 86.8% MRSA were found to be mul-
tiple drug resistant displaying resistances to more than 3
non-beta lactam drugs. No particular phenotypic antibiotic
susceptible pattern was seen for either SCCmec type. Molec-
ular characterization showed the replacement of nosocomial
SCCmec types with CA-MRSA SCCmec types in hospital.
Conclusion: SCCmec type V has become the predomi-
nant type in clinical setting. However a nationwide study
is needed to know the actual scenario. The predominance
of CA-MRSA in hospital shows that it has become a successful
nosocomial pathogen which will have signiﬁcant impact on
the control of MRSA. Well-designed, community based stud-
